We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SAMARITAN RELEASES RESULTS OF ALZHEIMER'S DRUG ANIMAL STUDY

SAMARITAN RELEASES RESULTS OF ALZHEIMER'S DRUG ANIMAL STUDY

July 12, 2006

Samaritan Pharmaceuticals has announced animal study results that show its Alzheimer's drug SP-233 (caprospinol) not only stops amyloid plaque formation in the brain of an animal model, but also that treatment with caprospinol results in the disappearance of amyloid plaques in the brain.

This new study, conducted in a rat animal model of Alzheimer's disease and led by Samaritan collaborating researchers at Georgetown University, found that rats exhibiting an Alzheimer's disease-like phenotype treated with a placebo solution retained amyloid plaques formed in the hippocampus and cortex of the brain, whereas, rats treated with caprospinol found no detectable amyloid plaques.

Caprospinol demonstrates neuroprotective properties in preclinical studies. In vitro studies have demonstrated that caprospinol directly binds to beta-amyloid peptide, inhibits the formation of neurotoxic amyloid-derived diffusible ligands and protects the mitochondria function by a direct action of the peptide on the organelle, thus protecting neuronal cells from beta-amyloid-induced toxicity.

KEYWORDS Drug Pipeline Alert

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing